New Research Areas

A number of drugs in development for PD have been discontinued. These include melevodopa; irreversible MAO-B inhibitors (e.g., rasagaline 67); newer COMT inhibitors (eBIA-3-202); DA (brasofensine) and monoamine reuptake inhibitors (SPD-743, 68); DA receptor agonists, in particular D2 full (e.g., rotigotine; sumanirole, now discontinued) or partial agonists, in combination with 5HT1A agonist activity (e.g., SLV-473; DU-127090, 69) or a2-adrenoceptor agonist activity (e.g., talipexole, 70); and a variety of neuroprotectants, including the immunophilins (e.g., GPI1046, 71; V10367, 72), mixed-lineage kinase (MLK) inhibitors (e.g., CEP-1347, 73), glyceraldehyde phosphate dehydrogenase (GAPDH) inhibitors (e.g., TCH-346, 74), growth factor agonists (e.g., leteprenim, an NGF agonist), modulators of astrocytic glutamate release (ONO-2506, 75), and AMPA antagonists (e.g., E-2007, 76).70 Adenosine A2A receptor antagonists, e.g., istradefylline 77,73 appear to be the most robust of the replacement therapies beyond DA replacement.

Blood Pressure Health

Blood Pressure Health

Your heart pumps blood throughout your body using a network of tubing called arteries and capillaries which return the blood back to your heart via your veins. Blood pressure is the force of the blood pushing against the walls of your arteries as your heart beats.Learn more...

Get My Free Ebook

Post a comment